MDS

Luspatercept in Low-Risk MDS

View All

Panel of four medical experts discussing managing side effects of Luspatercept in a professional setting.

Luspatercept in Low-Risk MDS

06/25/2026

Managing Side Effects of Luspatercept

Christopher Benton, MDJamile M. Shammo, MDTiffany Tanaka, MDAmer Zeidan, MBBS, MDRohit Gosain, MD

Image featuring Dr. Jamile M. Shammo, Dr. Tiffany Tanaka, Dr. Rohit Gosain, Dr. Amer Zeidan, and Dr. Christopher Benton discussing low-risk MDS and clinical trial data.

Luspatercept in Low-Risk MDS

06/24/2026

Luspatercept: Clinical Trial Data and Lessons for Low-Risk MDS

Christopher Benton, MDJamile M. Shammo, MDTiffany Tanaka, MDAmer Zeidan, MBBS, MDRohit Gosain, MD

Panel of four medical experts discussing recent advancements in defining, diagnosing, and staging myelodysplastic syndromes (MDS) for oncology updates.

Luspatercept in Low-Risk MDS

06/23/2026

Recent Advancements in Defining, Diagnosing, and Staging MDS

Christopher Benton, MDJamile M. Shammo, MDTiffany Tanaka, MDAmer Zeidan, MBBS, MDRohit Gosain, MD

Panel of four hematology experts discussing Luspatercept and low-risk MDS treatment strategies in a medical webinar.

Luspatercept in Low-Risk MDS

06/22/2026

Treating Low-Risk MDS After the Introduction of Luspatercept

Christopher Benton, MDJamile M. Shammo, MDTiffany Tanaka, MDAmer Zeidan, MBBS, MDRohit Gosain, MD

Expert panel discussing recent advances in Luspatercept treatment for LR-MDS, highlighting evolving strategies and clinical insights.

Luspatercept in Low-Risk MDS

06/12/2026

The Treatment Paradigm for Low-Risk MDS and the Impact of Luspatercept

Christopher Benton, MDJamile M. Shammo, MDTiffany Tanaka, MDAmer Zeidan, MBBS, MDRohit Gosain, MD